Mostrar el registro sencillo del ítem

Perfil de prolactina y estradiol en una cohorte de mujeres colombianas con lupus eritematoso sistémico

dc.contributor.advisorGranados, Carlos Eduardo
dc.contributor.advisorZubiría, Alberto de
dc.contributor.authorAulestia Baldeón, Elcie Carolina
dc.date.accessioned2013-12-16T17:54:36Z
dc.date.available2013-12-16T17:54:36Z
dc.date.created2013
dc.date.issued2013-12-16
dc.identifier.citationClowse MEB. Lupus activity in pregnancy. Rheum. Dis. Clin. North Am. 2007 May;33(2):237–252, v.
dc.identifier.citationKotzin BL. Systemic lupus erythematosus. Cell. 1996 May;85(3):303–6.
dc.identifier.citationSzyper-Kravitz M, Zandman-Goddard G, Lahita RG, Shoenfeld Y. The neuroendocrine-immune interactions in systemic lupus erythematosus: a basis for understanding disease pathogenesis and complexity. Rheum. Dis. Clin. North Am. 2005 Feb;31(1):161–175, x
dc.identifier.citationNikpour M, Urowitz MB, Ibañez D, Gladman DD. Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus. Arthritis Rheum. 2009;61(9):1152–8.
dc.identifier.citationPetri M. Sex hormones and systemic lupus erythematosus. Lupus. 2008 May;17(5):412–5
dc.identifier.citationCrow MK. Developments in the clinical understanding of lupus. Arthritis Res. Ther. 2009;11(5):245.
dc.identifier.citationCabrera JMA, D CAC, S RC, V PAC. Autoinmunidad y enfermedad autoinmune. Corporación para Investigaciones Biológicas; 2005. p. 557.
dc.identifier.citationLim SS, Drenkard C. Epidemiology of systemic lupus erythematosus: capturing the butterfly. Curr. Rheumatol. Rep. 2008 Aug;10(4):265–72
dc.identifier.citationPons-Estel GJ, Alarcón GS, Scofield L, Reinlib L, Cooper GS. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin. Arthritis Rheum. 2010 Feb;39(4):257–68.
dc.identifier.citationTikly M, Navarra S V. Lupus in the developing world--is it any different? Best Pract. Res. Clin. Rheumatol. 2008 Aug;22(4):643–55.
dc.identifier.citationVasudevan A, Krishnamurthy AN. Changing worldwide epidemiology of systemic lupus erythematosus. Rheum. Dis. Clin. North Am. 2010 Feb;36(1):1–13, vii.
dc.identifier.citationTan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 Nov;25(11):1271–7.
dc.identifier.citationCrow MK. MD Consult: Goldman: Cecil Medicine, 23rd ed. [Internet]. 2007 [cited 2011 Jan 15]. Available from: http://www.mdconsult.com/books/page
dc.identifier.citationPetri M, Genovese M, Engle E, Hochberg M. Definition, incidence, and clinical description of flare in systemic lupus erythematosus. A prospective cohort study. Arthritis Rheum. 1991 Aug;34(8):937–44.
dc.identifier.citationBombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992 Jun;35(6):630–40.
dc.identifier.citationGladman DD, Goldsmith CH, Urowitz MB, Bacon P, Bombardier C, Isenberg D, et al. Sensitivity to change of 3 Systemic Lupus Erythematosus Disease Activity Indices: international validation. J. Rheumatol. 1994 Aug;21(8):1468–71.
dc.identifier.citationRamsey-Goldman R, Isenberg DA. Systemic lupus erythematosus measures: British Isles Lupus Assessment Group (BILAG), European Consensus Lupus Activity Measurement (ECLAM), Systemic Lupus Activity Measure (SLAM), Systemic Lupus Erythematosus Disease Activity Measure (SLEDAI), and Systemi. Arthritis Rheum. 2003;49(S5):S225–S233.
dc.identifier.citationSymmons DP, Coppock JS, Bacon PA, Bresnihan B, Isenberg DA, Maddison P, et al. Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus. Members of the British Isles Lupus Assessment Group (BILAG). Q. J. Med. 1988 Nov;69(259):927–37.
dc.identifier.citationRogerio A. Lobo. MD Consult: Katz: Comprehensive Gynecology, Chapter 4 – Reproductive Endocrinology : Neuroendocrinology, Gonadotropins, Sex Steroids, Prostaglandins, Ovulation, Menstruation, Hormone Assay. Ovarian Steroids [Internet]. 2007 [cited 2011 Jan 16]. Available from: http://www.mdconsult.com/books
dc.identifier.citationDemura R, Suzuki T, Tajima S, Mitsuhashi S, Odagiri E, Demura H, et al. Human plasma free activin and inhibin levels during the menstrual cycle. J Clin Endocrinol Metab. 1993 Apr;76(4):1080–2.
dc.identifier.citationGruber CJ, Tschugguel W, Schneeberger C, Huber JC. Production and actions of estrogens. N. Engl. J. Med. 2002 Jan;346(5):340–52
dc.identifier.citationCohen-Solal JFG, Jeganathan V, Grimaldi CM, Peeva E, Diamond B. Sex hormones and SLE: influencing the fate of autoreactive B cells. Curr. Top. Microbiol. Immunol. 2006;305:67–88.
dc.identifier.citationEdward Rose, Donald Pillsbury. LUPUS ERYTHEMATOSUS (ERYTHEMATODES) AND OVARIAN FUNCTION: OBSERVATIONS ON A POSSIBLE RELATIONSHIP, WITH REPORT OF SIX CASES*. 1944 Dec;21(6):1022–34
dc.identifier.citationCohen-Solal JFG, Jeganathan V, Hill L, Kawabata D, Rodriguez-Pinto D, Grimaldi C, et al. Hormonal regulation of B-cell function and systemic lupus erythematosus. Lupus. 2008 Jun;17(6):528–32.
dc.identifier.citationGrimaldi CM. Sex and systemic lupus erythematosus: the role of the sex hormones estrogen and prolactin on the regulation of autoreactive B cells. Curr. Opin. Rheumatol. 2006 Sep;18(5):456–61.
dc.identifier.citationMcMurray RW, May W. Sex hormones and systemic lupus erythematosus: Review and meta-analysis. Arthritis Rheum. 2003;48(8):2100–10.
dc.identifier.citationFolomeev M, Dougados M, Beaune J. Plasma sex hormones and aromatase activity in tissues of patients with systemic lupus erythematosus. Lupus. 1992 May;1(3):191–5
dc.identifier.citationRoubinian J, Talal N, Siiteri PK, Sadakian JA. Sex hormone modulation of autoimmunity in NZB/NZW mice. Arthritis Rheum. 1979;22(11):1161–9.
dc.identifier.citationVerthelyi D, Ansar Ahmed S. Characterization of estrogen-induced autoantibodies to cardiolipin in non-autoimmune mice. J. Autoimmun. 1997 Apr;10(2):115–25.
dc.identifier.citationKassi E, Moutsatsou P. Estrogen receptor signaling and its relationship to cytokines in systemic lupus erythematosus. J. Biomed. Biotechnol. 2010 Jan;2010:1–14.
dc.identifier.citationGomez, G, Posada, G, Martinez, C. Prolactina Y Prolactinomas: Una vision global. Rev. Colomb. Menopaus. 2000;6(3):244–69
dc.identifier.citationMadhusoodanan S, Parida S, Jimenez C. Hyperprolactinemia associated with psychotropics--a review. Hum. Psychopharmacol. 2010 Jun;25(4):281–97.
dc.identifier.citationGuber HA, Farag AF, Tumors P. Evaluation of Endocrine Function. In: McPherson RA, Pincus MR, editors. Henry’s Clin. Diagnosis Manag. by Lab. Methods. Twenty sec. Philadelphia: Elsevier Inc.; 2011. p. 365–401.
dc.identifier.citationLobo, R. MD Consult: Katz: Comprehensive Gynecology. Chapter 39 – Hyperprolactinemia, Galactorrhea, and Pituitary Adenomas : Etiology, Differential Diagnosis, Natural History, Management. 5th ed. Mosby Elsevier; 2007.
dc.identifier.citationMcPherson RA, Pincus MR, Henry JB. Henry’s clinical diagnosis and management by laboratory methods. 21st ed. Saunders Elsevier; 2007. p. 1484.
dc.identifier.citationSIEVERTSEN GD, LIM VS, NAKAWATASE C, FROHMAN LA. Metabolic Clearance and Secretion Rates of Human Prolactin in Normal Subjects and in Patients with Chronic Renal Failure. J Clin Endocrinol Metab. 1980 May;50(5):846–52.
dc.identifier.citationChuang E, Molitch ME. Prolactin and autoimmune diseases in humans. Acta BioMedica Atenei Parm. 2007;78 Suppl 1:255–61.
dc.identifier.citationRussell DH. New aspects of prolactin and immunity: a lymphocyte-derived prolactin-like product and nuclear protein kinase C activation. Trends Pharmacol. Sci. 1989 Jan;10(1):40–4.
dc.identifier.citationSaha S, Tieng A, Pepeljugoski KP, Zandamn-Goddard G, Peeva E. Prolactin, systemic lupus erythematosus, and autoreactive B cells: lessons learnt from murine models. Clin. Rev. Allergy Immunol. 2011 Feb;40(1):8–15.
dc.identifier.citationJacobi a., Rohde W, Ventz M, Riemekasten G, Burmester G-R, Hiepe F. Enhanced serum prolactin (PRL) in patients with systemic lupus erythematosus: PRL levels are related to the disease activity. Lupus. 2001 Aug 1;10(8):554–61.
dc.identifier.citationJara LJ, Gomez-Sanchez C, Silveira LH, Martinez-Osuna P, Vasey FB, Espinoza LR. Hyperprolactinemia in systemic lupus erythematosus: association with disease activity. Am. J. Med. Sci. 1992 Apr;303(4):222–6.
dc.identifier.citationRovenský J, Juránková E, Rauová L, Blazícková S, Lukác J, Veselková Z, et al. Relationship between endocrine, immune, and clinical variables in patients with systemic lupus erythematosus. J. Rheumatol. 1997 Dec;24(12):2330–4.
dc.identifier.citationSaha S, Gonzalez J, Rosenfeld G, Keiser H, Peeva E. Prolactin alters the mechanisms of B cell tolerance induction. Arthritis Rheum. 2009 Jun;60(6):1743– 52.
dc.identifier.citationPeeva E, Michael D, Cleary J, Rice J, Chen X, Diamond B. Prolactin modulates the naive B cell repertoire. J. Clin. Invest. 2003 Jan;111(2):275–83.
dc.identifier.citationRezanka LJ, Kenny JJ, Longo DL. Dual isotype expressing B cells [[kappa](+)/[lambda](+)] arise during the ontogeny of B cells in the bone marrow of normal nontransgenic mice. Cell. Immunol. 2005 Nov;238(1):38–48.
dc.identifier.citationRice JS, Newman J, Wang C, Michael DJ, Diamond B. Receptor editing in peripheral B cell tolerance. Proc. Natl. Acad. Sci. U. S. A. 2005 Mar 1;102(5):1608–13
dc.identifier.citationRadic MZ, Erikson J, Litwin S, Weigert M. B lymphocytes may escape tolerance by revising their antigen receptors. J. Exp. Med. 1993 Apr 1;177(4):1165–73.
dc.identifier.citationNossal GJ, Pike BL. Clonal anergy: persistence in tolerant mice of antigen-binding B lymphocytes incapable of responding to antigen or mitogen. Proc. Natl. Acad. Sci. U. S. A. 1980 Mar;77(3):1602–6.
dc.identifier.citationMerrell KT, Benschop RJ, Gauld SB, Aviszus K, Decote-Ricardo D, Wysocki LJ, et al. Identification of Anergic B Cells within a Wild-Type Repertoire. Immunity. 2006;25(6):953–62.
dc.identifier.citationGauld SB, Benschop RJ, Merrell KT, Cambier JC. Maintenance of B cell anergy requires constant antigen receptor occupancy and signaling. Nat. Immunol. 2005 Nov;6(11):1160–7
dc.identifier.citationJara LJ, Medina G, Saavedra MA, Vera-Lastra O, Navarro C. Prolactin and autoimmunity. Clin. Rev. Allergy Immunol. 2011 Feb;40(1):50–9.
dc.identifier.citationJara LJ, Lavalle C, Espinoza LR. Does prolactin have a role in the pathogenesis of systemic lupus erythematosus? J. Rheumatol. 1992 Sep;19(9):1333–6.
dc.identifier.citationWalker SE, McMurray RW, Houri JM, Allen SH, Keisler D, Sharp GC, et al. Effects of prolactin in stimulating disease activity in systemic lupus erythematosus. Ann. N. Y. Acad. Sci. 1998 May;840:762–72.
dc.identifier.citationMcMurray RW. Prolactin and systemic lupus erythematosus. Ann. Med. Interne (Paris). 1996;147(4):253–8.
dc.identifier.citationLahita RG, Bradlow HL, Kunkel HG, Fishman J. Alterations of estrogen metabolism in systemic lupus erythematosus. Arthritis Rheum. 1979 Nov;22(11):1195–8.
dc.identifier.citationZen M, Ghirardello A, Iaccarino L, Tonon M, Campana C, Arienti S, et al. Hormones, immune response, and pregnancy in healthy women and SLE patients. Swiss Med. Wkly. 2010 Apr;140(13-14):187–201.0
dc.identifier.citationIsenberg DA. BILAG, SLEDAI, SIS, ECLAM, WAM, SLAM .... thank you MAM. Lupus. 2007;16(11):849–51.
dc.identifier.citationP. Tsao, B., Hannahs, B. Firestein: Kelley’s Textbook of Rheumatology - Part 11 Systemic Lupus Eritematosus and Related Syndromes. 8th ed. W.B. Saunders Company; 2008. p. Ch 75.
dc.identifier.citationCarroll M V., Sim RB. Complement in health and disease. Adv. Drug Deliv. Rev. Elsevier B.V.; 2011 Sep 16;63(12):965–75.
dc.identifier.citationJulkunen H, Ekblom-Kullberg S, Miettinen A. Nonrenal and renal activity of systemic lupus erythematosus: a comparison of two anti-C1q and five anti-dsDNA assays and complement C3 and C4. Rheumatol. Int. 2011 Jun
dc.identifier.citationAmezcua-Guerra LM, Springall R, Arrieta-Alvarado AA, Rodríguez V, RiveraMartinez E, Castillo-Martinez D, et al. C-reactive protein and complement components but not other acute-phase reactants discriminate between clinical subsets and organ damage in systemic lupus erythematosus. Clin. Lab. 2011;57(7-8):607–13.
dc.identifier.citationMersereau J, Dooley MA. Gonadal failure with cyclophosphamide therapy for lupus nephritis: advances in fertility preservation. Rheum. Dis. Clin. North Am. 2010 Feb;36(1):99–108, viii.
dc.identifier.citationTehseen I, Khemomal K, Shehnaz S, Khemomal K. SYSTEMIC LUPUS ERYTHEMATOSUS, FEMALE OF FERTILE AGE CHANGES IN REPRODUCTIVE HORMONES ESTROGEN AND PROLACTIN LEVELS. Prof. Med. J. 2011;18(2):255–8.
dc.identifier.citationShabanova SS, Ananieva LP, Alekberova ZS, Guzov II. Ovarian function and disease activity in patients with systemic lupus erythematosus. Clin. Exp. Rheumatol. 2008;26(3):436–41.
dc.identifier.citationTiskievicz F, Mallmann ES. Prolactina, estradiol e anticorpos anticardiolipina em amostra de mulheres pré-menopáusicas com lúpus eritematoso sistêmico: estudo-piloto. Rev Bras Reum. 2011;51(5):456–64.
dc.identifier.citationWeidler C, Härle P, Schedel J, Schmidt M, Schölmerich J, Straub RH. Patients with rheumatoid arthritis and systemic lupus erythematosus have increased renal excretion of mitogenic estrogens in relation to endogenous antiestrogens. J. Rheumatol. 2004 Mar;31(3):489–94
dc.identifier.citationWang J, Nuite M, McAlindon TE. Association of estrogen and aromatase gene polymorphisms with systemic lupus erythematosus. Lupus. 2010 May;19(6):734– 40.
dc.identifier.citationDagtas A, Moussai D, Diamond B. Estrogen alters thresholds for B cell apoptosis and activation. J. Clin. 2002;109(12):1625–33
dc.identifier.citationThien M, Phan TG, Gardam S, Amesbury M, Basten A, Mackay F, et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity. 2004 Jun;20(6):785–98.
dc.identifier.citationVenkatesh J, Peeva E, Xu X, Diamond B. Cutting Edge: Hormonal milieu, not antigenic specificity, determines the mature phenotype of autoreactive B cells. J. Immunol. 2006 Mar 15;176(6):3311–4.
dc.identifier.citationRider V, Jones SR, Evans M, Abdou NI. Molecular mechanisms involved in the estrogen-dependent regulation of calcineurin in systemic lupus erythematosus T cells. Clin. Immunol. 2000 May;95(2):124–34.
dc.identifier.citationRider V, Keltner S, Abdou NI. Increased estrogen-dependent expression of calcineurin in female SLE T cells is regulated by multiple mechanisms. J. Gend. Specif. Med. 2003 Jan;6(2):14–21
dc.identifier.citationKim W-U, Min S-Y, Hwang S-H, Yoo S, Kim K-J, Cho C-S. Effect of oestrogen on T cell apoptosis in patients with systemic lupus erythematosus. Clin. Exp. Immunol. 2010 Sep;161(3):453–8
dc.identifier.citationFeng F, Nyland J, Banyai M, Tatum A, Silverstone AE, Gavalchin J. The induction of the lupus phenotype by estrogen is via an estrogen receptor-alpha-dependent pathway. Clin. Immunol. Elsevier Inc.; 2010 Feb;134(2):226–36
dc.identifier.citationBynoté KK, Hackenberg JM, Korach KS, Lubahn DB, Lane PH, Gould K a. Estrogen receptor-alpha deficiency attenuates autoimmune disease in (NZB x NZW)F1 mice. Genes Immun. 2008 Mar;9(2):137–52.
dc.identifier.citationPotier M, Elliot SJ, Tack I, Lenz O, Striker GE, Striker LJ, et al. Expression and regulation of estrogen receptors in mesangial cells: influence on matrix metalloproteinase-9. J. Am. Soc. Nephrol. 2001 Feb;12(2):241–51
dc.identifier.citationPotier M, Karl M, Zheng F, Elliot SJ, Striker GE, Striker LJ. Estrogen-related abnormalities in glomerulosclerosis-prone mice: reduced mesangial cell estrogen receptor expression and prosclerotic response to estrogens. Am. J. Pathol. 2002 May;160(5):1877–85.
dc.identifier.citationElliot SJ, Karl M, Berho M, Potier M, Zheng F, Leclercq B, et al. Estrogen deficiency accelerates progression of glomerulosclerosis in susceptible mice. Am. J. Pathol. 2003 May;162(5):1441–8.
dc.identifier.citationShim G-J, Kis LL, Warner M, Gustafsson J-A. Autoimmune glomerulonephritis with spontaneous formation of splenic germinal centers in mice lacking the estrogen receptor alpha gene. Proc. Natl. Acad. Sci. U. S. A. 2004 Feb 10;101(6):1720–4.
dc.identifier.citationHan HJ, Park SH, Park HJ, Park KM, Kang JW, Lee JH, et al. Effect of various oestrogens on cell injury and alteration of apical transporters induced by tert-butyl hydroperoxide in renal proximal tubule cells. Clin. Exp. Pharmacol. Physiol. 29(1- 2):60–7.
dc.identifier.citationIrsik DL, Carmines PK, Lane PH. Classical Estrogen Receptors and ERα Splice Variants in the Mouse. PLoS One. 2013 Jan;8(8):e70926.
dc.identifier.citationWu WM, Lin BF, Su YC, Suen JL, Chiang BL. Tamoxifen decreases renal inflammation and alleviates disease severity in autoimmune NZB/W F1 mice. Scand. J. Immunol. 2000 Oct;52(4):393–400.
dc.identifier.citationSthoeger ZM, Zinger H, Mozes E. Beneficial effects of the anti-oestrogen tamoxifen on systemic lupus erythematosus of (NZBxNZW)F1 female mice are associated with specific reduction of IgG3 autoantibodies. Ann. Rheum. Dis. 2003 Apr;62(4):341–6.
dc.identifier.citationAbdou NI, Rider V, Greenwell C, Li X, Kimler BF. Fulvestrant (Faslodex), an estrogen selective receptor downregulator, in therapy of women with systemic lupus erythematosus. clinical, serologic, bone density, and T cell activation marker studies: a double-blind placebo-controlled trial. J. Rheumatol. 2008 May;35(5):797.
dc.identifier.citationQu X a, Gudivada RC, Jegga AG, Neumann EK, Aronow BJ. Inferring novel disease indications for known drugs by semantically linking drug action and disease mechanism relationships. BMC Bioinformatics. 2009 Jan;10 Suppl 5:S4.
dc.identifier.citationSingh MN, Martin-Hirsch PL, Martin FL. The multiple applications of tamoxifen: an example pointing to SERM modulation being the aspirin of the 21st century. Med. Sci. Monit. 2008 Sep;14(9):RA144–8.
dc.identifier.citationRezaieyazdi Z, Hesamifard A. Correlation between serum prolactin levels and lupus activity. Rheumatol. Int. 2006 Sep;26(11):1036–9.
dc.identifier.citationHaghighi A, Lahmi F. Hyperprolactinemia in patients with systemic lupus erythematosus: correlation with disease activity. APLAR J. Rheumatol. 2006 Sep;9(3):227–31.
dc.identifier.citationMok CC, Lau CS, Tam SC. Prolactin profile in a cohort of Chinese systemic lupus erythematosus patients. Br. J. Rheumatol. 1997 Sep;36(9):986–9.
dc.identifier.citationMoszkorzová L, Lacinová Z, Marek J, Musilová L, Dohnalová A, Dostál C. Hyperprolactinaemia in patients with systemic lupus erythematosus. Clin. Exp. Rheumatol. 2002;20(6):807–12.
dc.identifier.citationJara LJ, Vera-Lastra O, Miranda JM, Alcala M, Alvarez-Nemegyei J. Prolactin in human systemic lupus erythematosus. Lupus. 2001;10(10):748–56
dc.identifier.citationJokar M, Maybodi NT, Amini A, Fard MH. Prolactin and macroprolactin in patients with systemic lupus erythematosus. Int. J. Rheum. Dis. 2008 Sep;11(3):257–62
dc.identifier.citationJara LJ, Pacheco-Reyes H, Medina G, Angeles U, Cruz-Cruz P, Saavedra M a. Prolactin Levels Are Associated with Lupus Activity, Lupus Anticoagulant, and Poor Outcome in Pregnancy. Ann. N. Y. Acad. Sci. 2007 Jun 1;1108(1):218–26
dc.identifier.citationKarimifar M, Tahmasebi A, Bonakdar ZS, Purajam S. Correlation of serum prolactin levels and disease activity in systematic lupus erythematosus. Rheumatol. Int. 2013 Feb;33(2):511–6
dc.identifier.citationBuskila D, Lorber M, Neumann L, Flusser D, Shoenfeld Y. No correlation between prolactin levels and clinical activity in patients with systemic lupus erythematosus. J. Rheumatol. 1996 Apr;23(4):629–32.
dc.identifier.citationStevens a., Ray DW, Worthington J, Davis JR. Polymorphisms of the human prolactin gene—implications for production of lymphocyte prolactin and systemic lupus erythematosus. Lupus. 2001 Oct 1;10(10):676–83.
dc.identifier.citationSabharwal P, Glaser R, Lafuse W, Varma S, Liu Q, Arkins S, et al. Prolactin synthesized and secreted by human peripheral blood mononuclear cells: an autocrine growth factor for lymphoproliferation. Proc. Natl. Acad. Sci. U. S. A. 1992 Aug 15;89(16):7713–6.
dc.identifier.citationYu-Lee L. Stimulation of interferon regulatory factor-1 by prolactin. Lupus. 2001;10(10):691–9.
dc.identifier.citationYu-Lee LY. Molecular actions of prolactin in the immune system. Proc. Soc. Exp. Biol. Med. 1997 May;215(1):35–52.
dc.identifier.citationClevenger C V, Kline JB. Prolactin receptor signal transduction. Lupus. 2001 Jan;10(10):706–18.
dc.identifier.citationDostál C, Moszkorzová L, Musilová L, Lacinová Z, Marek J, Zvárová J. Serum prolactin stress values in patients with systemic lupus erythematosus. Ann. Rheum. Dis. 2003 May;62(5):487–8.
dc.identifier.citationMcMurray RW, Weidensaul D, Allen SH, Walker SE. Efficacy of bromocriptine in an open label therapeutic trial for systemic lupus erythematosus. J. Rheumatol. 1995 Nov;22(11):2084–91.
dc.identifier.citationAlvarez-Nemegyei J, Cobarrubias-Cobos A, Escalante-Triay F, Sosa-Muñoz J, Miranda JM, Jara LJ. Bromocriptine in systemic lupus erythematosus: a doubleblind, randomized, placebo-controlled study. Lupus. 1998;7(6):414–9.
dc.identifier.citationWalker SE. Modulation of hormones in the treatment of lupus. Am. J. Manag. Care. 2001 Oct;7(16 Suppl):S486–489.
dc.identifier.citationJara LJ, Cruz-Cruz P, Saavedra M a, Medina G, García-Flores A, Angeles U, et al. Bromocriptine during pregnancy in systemic lupus erythematosus: a pilot clinical trial. Ann. N. Y. Acad. Sci. 2007 Sep;1110:297–304.
dc.identifier.citationOrbach H, Zandman-Goddard G, Amital H, Barak V, Szekanecz Z, Szucs G, et al. Novel biomarkers in autoimmune diseases: prolactin, ferritin, vitamin D, and TPA levels in autoimmune diseases. Ann. N. Y. Acad. Sci. 2007 Aug;1109:385–400.
dc.identifier.citationOertelt-Prigione S. Immunology and the menstrual cycle. Autoimmun. Rev. Elsevier B.V.; 2012 May;11(6-7):A486–92.
dc.identifier.citationSteinberg AD, Steinberg BJ. Lupus disease activity associated with menstrual cycle. J. Rheumatol. 1985 Aug;12(4):816–7.
dc.identifier.citationPasoto SG, Mendonça BB, Bonfá E. Menstrual disturbances in patients with systemic lupus erythematosus without alkylating therapy: clinical, hormonal and therapeutic associations. Lupus. 2002 Jan;11(3):175–80.
dc.identifier.citationMedeiros PB, Febrônio M V, Bonfá E, Borba EF, Takiuti AD, Silva CAA. Menstrual and hormonal alterations in juvenile systemic lupus erythematosus. Lupus. 2009 Jan;18(1):38–43.
dc.identifier.citationColangelo K, Haig S, Bonner A, Zelenietz C, Pope J. Self-reported flaring varies during the menstrual cycle in systemic lupus erythematosus compared with rheumatoid arthritis and fibromyalgia. Rheumatology (Oxford). 2011 Apr;50(4):703–8
dc.identifier.urihttp://hdl.handle.net/10818/9372
dc.description60 Páginas.
dc.description.abstractEl Lupus Eritematoso Sistémico (LES) es un una enfermedad autoinmune con afectación multisistémica de gran variabilidad en su presentación y curso. Su diagnóstico se basa en características clínicas y de laboratorio en ausencia de otra enfermedad autoinmune que pueda explicar dichos hallazgos. Aunque el LES puede desarrollarse a cualquier edad, las mujeres en edad fértil son las principalmente afectadas. La relación mujer/hombre entre los 15 y 50 años de edad es > 8:1, mientras que llega a ser hasta 2:1 cuando ocurre durante la niñez o después de la menopausia. Esta prevalencia observada tanto en pacientes como en modelos animales, ha llevado a plantear la intervención de hormonas en el desarrollo y actividad de la misma. La relación entre el sistema neuroendocrino y el sistema inmune ha sido ampliamente demostrada. Comparten una red de conexiones mediadas por vías nerviosas, circuitos hormonales, interacciones celulares y humorales, así como una multitud de citoquinas, neuropéotidos y quemoquinas. De una interacción recíproca y modulada entre ambos sistemas depende el mantenimiento de la homeostasis. El desarrollo de una enfermedad multisistémica como el LES es el resultado del rompimiento de la misma. El LES se caracteriza por periodos de exacerbaciones y remisiones de la actividad de la enfermedad. Varios determinantes de este comportamiento han sido estudiados, sin que se haya esclarecido uno en especial; sin embargo, derivado de estudios observacionales de estados fisiológicos relacionados con aumento de actividad (por ejemplo, el embarazo) varios autores han demostrado la asociación con algunas hormonas. Entre las principales que han demostrado tener un efecto inmuno-modulador se encuentran el estrógeno y la prolactina.es_CO
dc.language.isospaes_CO
dc.publisherUniversidad de La Sabana
dc.sourceUniversidad de La Sabana
dc.sourceIntellectum Repositorio Universidad de La Sabana
dc.subjectProlatina -- Investigaciones
dc.subjectEstradiol
dc.subjectLupus eritematoso cutáneo -- Piel -- Enfermedades
dc.titlePerfil de prolactina y estradiol en una cohorte de mujeres colombianas con lupus eritematoso sistémicoes_CO
dc.typebachelorThesis
dc.publisher.programEspecialización en Medicina Interna
dc.publisher.departmentFacultad de Medicina
dc.identifier.local256511
dc.identifier.localTE06227
dc.type.localTesis de especialización
dc.type.hasVersionpublishedVersion
dc.rights.accessRightsopenAccess
dc.creator.degreeEspecialista en Medicina Interna


Ficheros en el ítem

Thumbnail
Nombre:
Elcie Carolina Aulestia Baldeón ...
Tamaño:
1.587Mb
Formato:
PDF
Descripción:
Ver documento en PDF
Ver/

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem